Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adolescent Cancer Clear all
Recruiting Phase 2 Interventional

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

NCT06458036
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions
Selpercatinib Monotherapy, 131I Therapy
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

NCT04145700
View directory record Official record
Conditions
Synovial Sarcoma
Interventions
Ramucirumab, Gemcitabine, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

NCT00777036
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Results available

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

NCT04052334
View directory record Official record
Conditions
Sarcoma
Interventions
TIL, Interleukin-2, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

NCT07680439
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Interventions
BCB-276
Biological
Lead sponsor
BrainChild Bio, Inc
Industry
Eligibility
1 Year to 26 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 1 Interventional

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

NCT03826992
View directory record Official record
Conditions
Leukemia
Interventions
Vyxeos, Venetoclax
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 39 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

NCT05415007
View directory record Official record
Conditions
Cancer
Interventions
GOLD Program, Treatment as usual (TAU)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting No phase listed Observational

Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers

NCT06880861
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

NCT01626846
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
John Jay High School
Other
Eligibility
14 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cross River, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Active, not recruiting Not applicable Interventional

Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study

NCT05357469
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Immediate St (Scrambler Therapy), Waitlist ST (Scrambler Therapy)
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Navigating Financial and Health-Related Social Needs in Adolescent and Young Adult Cancer Survivors (AYA-NAV)

NCT06950983
View directory record Official record
Conditions
Cancer in Adolescence
Interventions
AYA-NAV
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
15 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Not listed Not applicable Interventional

Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

NCT01425541
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome (PCOS)
Interventions
estrace, Progesterone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 15, 2026, 7:52 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

NCT05228275
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 37 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer

NCT07139769
View directory record Official record
Conditions
Caregiving for Cancer
Interventions
Psychosocial Intervention for Parental Caregivers of AYA with Cancer
Behavioral
Lead sponsor
Zeba Ahmad, Ph.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

NCT02190721
View directory record Official record
Conditions
Neutropenia
Interventions
tbo-filgrastim
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Results available

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03813147
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Therapeutic Hydrocortisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors

NCT06848491
View directory record Official record
Conditions
Obesity, Cancer, Physical Activity, Cancer Survivorship, Diet
Interventions
AYA WELL Intervention, Self-Guided
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT01471782
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Biological
Lead sponsor
Amgen Research (Munich) GmbH
Industry
Eligibility
Up to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

NCT07725380
View directory record Official record
Conditions
Sarcoma, Osteosarcoma
Interventions
Domatinostat, Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
12 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

NCT00004228
View directory record Official record
Conditions
Lymphoma
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 15, 2026, 7:52 PM EDT
Active, not recruiting No phase listed Observational

Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images

NCT04125095
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

NCT02897232
View directory record Official record
Conditions
Papillomavirus Infections, Health Behavior, Attitude of Health Personnel, Human Papilloma Virus, Male
Interventions
Survey
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Early Phase 1 Interventional

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

NCT02484053
View directory record Official record
Conditions
Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 15, 2026, 7:52 PM EDT